Overview

Efficacy and Safety of TRK-700 in Patient With Post-Herpetic Neuralgia

Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
0
Participant gender:
All
Summary
In Post-Herpetic Neuralgia(PHN) patients: - To conduct an explorative investigation of the efficacy and safety of repeated oral doses of TRK-700 via a randomized double blind comparative study - To measure the plasma concentration of TRK-700 and its metabolites
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Toray Industries, Inc
Criteria
Inclusion Criteria:

- Patients with pain persisting for at least 3 months after the onset of herpes zoster

- Patients whose average pain score on the Numerical Rating Scale (NRS) over the past 24
hours at preliminary enrollment is at least 4

Exclusion Criteria:

- Patients with another skin disease that may affect the evaluation of the pain at the
site of PHN

- Patients with pain other than PHN that may affect the evaluation of pain

- Patients with pain that is suspected to be mainly psychogenic

- Patients who have received neurolytic or neurosurgical therapy for PHN